Securities Class Action Filed Against Rocket Pharmaceuticals Over Alleged Misstatements and Omissions
A securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc., a gene therapy company based in Cranbury, New Jersey. The lawsuit is on behalf of investors who purchased the company's stock between September 17, 2024, and May 26, 2025, and suffered losses due to alleged material misstatements and omissions. The claims revolve around the company's failure to disclose significant safety-related updates in its RP-A501 clinical trial, which included the use of an immunomodulatory agent, prior to a fatal adverse event and an FDA-imposed clinical hold. Following the public confirmation of the trial hold and patient death on May 28, 2025, Rocket Pharmaceuticals' shares saw a significant drop from $6.27 to $2.33. Investors seeking to serve as lead plaintiff in the case have until August 11, 2025, to come forward.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 259783) on July 23, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.